FDA puts new limits on Johnson & Johnson vaccine due to rare blood clotting condition

The FDA revised its emergency authorization to sharply limit the use of Johnson & Johnson's COVID-19 vaccine due to a rare but potentially fatal blood clotting condition called thrombosis with thrombocytopenia syndrome (TTS).